Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreBringing data science and human science together to advance human health and support the pharmaceutical industry from clinical trials to commercialization.
Learn MoreConnecting with powerful, evidence-based market insights to drive agile thinking, uncover growth potential, and gain competitive advantage in this fast-moving consumer health market.
LEARN MOREEmpowering to orchestrate operations across the entire product lifecycle, from concept-to-market, providing quality control, regulatory, safety and compliance solutions along the way.
Learn moreWorking across the health system to address key barriers to deliver high-quality, cost-effective care while improving health outcomes using our data-driven and population-centric solutions.
LEARN MOREDelivering a wide range of consulting and technology solutions to support healthcare stakeholders to drive operational efficiency, enhance quality of patient care, and improve systemic outcomes.
learn moreClinical development enabled by Connected Intelligence™ which combines data and analytics with deep therapeutic and operational expertise to improve efficiency, enhance precision, and bring therapies to patients faster.
Learn MoreHarness the power of real-world data and insights to demonstrate value-driven evidence and outcomes to meet stakeholder needs across the healthcare ecosystem and to propel healthcare forward.
LEARN MOREPharmaceutical market data and information assets that provide actionable data points to help organizations make intelligent connections and drive healthcare forward.
LEARN MOREPrimary Intelligence integrates purpose-built and syndicated research solutions with our wide range of data assets, research methodologies, advanced analytics, and deep domain expertise, generating quality insights for our clients.
LEARN MORETrusted advisor and partner to global healthcare organisations, solving the most significant business challenges through extensive healthcare expertise.
LEARN MOREOptimize commercial success by leveraging our comprehensive outsourced expertise to accelerate time-to-market.
LEARN MOREA single window solution provider to support pharmaco’s design, deploy technology and services that help increase access to medicine and improve treatment adherence.
LEARN MOREConnected Intelligence™, digital insights, data analytics and advanced technology to power smarter decision-making to enable better patient outcomes and improved business results.
LEARN MOREGet the latest insights on our life sciences, healthcare, and medical technology solutions in Asia Pacific.
Learn MoreExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
Discover Insights"A curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the Asia Pacific healthcare market.
Read The Latest Issue"Unlocking the Future of Consumer Health: A Special Focus on Senior Consumers
Learn MoreImproving human health requires innovative thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
Search JobsRespiratory Syncytial Virus (RSV) is a highly contagious respiratory pathogen causing severe lower respiratory tract diseases, particularly in older adults (age ≥60 years). Annually, RSV accounts for around 5.2 million cases and 33,000 in-hospital deaths among older adults in high-income countries. Factors like immune decline, lung aging, and comorbidities increase susceptibility.
The economic impact of RSV on healthcare systems in high-income Asia-Pacific Economic Cooperation (APEC) countries (China, Japan, South Korea, Canada, Singapore, New Zealand, Australia, Hong Kong, Taiwan) is significant but challenging to quantify due to insufficient epidemiological and healthcare resource data for older adults. Routine RSV testing is uncommon due to non-specific symptoms overlapping with other infections. Diagnosis often relies on local epidemiology rather than lab tests, leading to inconsistent testing methods.
Our study estimated the clinical and economic burden of RSV among older adults in high-income APEC countries. A literature review identified evidence on the incidence and costs associated with RSV hospitalizations. In 2023, RSV caused approximately 778,000 hospitalizations and USD 2.8 billion in costs. The highest estimated burden was seen in China, followed by Japan and Canada. On average, 1 in 500 older adults were hospitalized annually, with hospitalization costs ranging from USD 2,735 in New Zealand to USD 12,826 in Canada.
Therefore, there is a need for an urgent strategic mitigation plan to address the growing burden of RSV infection. Our study's data will guide future prevention programs and be crucial for regulatory decision-making and healthcare planning. These measures will help ease the RSV burden on healthcare systems and economies. Read the full white paper for more insights.